iRhythm Technologies Inc. Appoints Marga Ortigas-Wedekind Executive Vice President, Global Marketing

SAN FRANCISCO, July 21, 2015 /PRNewswire/ -- iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on advancing cardiac care, announced today that Marga Ortigas-Wedekind, an experienced healthcare and medical device marketing and product development leader, has joined the company's senior management as executive vice president, global marketing.

In this role, Ortigas-Wedekind will be responsible for developing and executing the marketing strategy for iRhythm's ZIO® Service, which combines wearable biosensor devices with mobile and cloud-based technology to improve the diagnosis and treatment of arrhythmias.  Under Ortigas-Wedekind's leadership, iRhythm will develop a global brand architecture to accelerate widespread awareness for the ZIO® Service and its benefits.  She will also work with payers to develop comprehensive reimbursement strategies to support iRhythm in launching new products and entering new markets.

"Marga brings to iRhythm a proven track record of leading successful global marketing and product development strategies for high growth medical device and healthcare companies," said Kevin King, president and chief executive officer of iRhythm Technologies.  "Over the past several years, iRhythm has a built a strong foundation of support among payers, large health systems, physicians and patients.  We look forward to leveraging Marga's proven expertise in driving growth through innovative marketing and branding strategies to build on this momentum to take iRhythm to the next level."

Prior to joining iRhythm, Ortigas-Wedekind was executive vice president, global marketing and product development for Omnicell Inc., a provider of automated medication and medical supply dispensing systems for healthcare facilities.  In this role, Ortigas-Wedekind helped drive the company's growth by tripling market share for Omnicell's core business through directing the development and launch of the company's most successful product introduction.  During her career, Ortigas-Wedekind has held senior marketing and development roles at companies spanning large corporations such as Guidant Corporation, where she developed marketing strategies for its Vascular Intervention business, to rapidly growing start-ups such as Xoft, Inc. with disruptive technology for radiation therapy delivery.

Ortigas-Wedekind received her MBA in international business and marketing from Stanford and her BA, cum laude, at Wellesley College, where she cross-registered at Massachusetts Institute of Technology Sloan School of Management.

"I am thrilled to join iRhythm at this pivotal time of expansion for the ZIO® Service," said Ortigas-Wedekind. "iRhythm is already experiencing impressive growth with its proven high-value, low cost digital health solution that improves the diagnosis and treatment of arrhythmia, a condition that impacts more than four million people in the U.S. alone. I look forward to working with this top-notch team to drive future growth and build a world- class brand."

The ZIO® Service is the world's first and long-term continuous monitoring service that is FDA-cleared and supported by extensive clinical data with peer-reviewed publications. The ZIO® Service has been clinically proven to enhance clinical decision making and drive lower healthcare costs. Since its commercial launch in 2011, it has been used by nearly 400,000 patients at over 1,000 institutions in the U.S. Analytics collected from ZIO® monitoring can be used to identify early and effective treatment options, prevent potential clinical issues and reduce readmissions.

About iRhythm Technologies, Inc.
iRhythm is a global leader in digital healthcare solutions that address cardiac arrhythmia. We combine wearable biosensor devices with mobile and cloud-based technology to improve how heart arrhythmias are diagnosed and managed.  iRhythm's digital health technology and diagnostic support services provide clear, actionable information for physicians, and are clinically proven to enhance clinical decisions and reduce healthcare costs.  Our flagship solution, the ZIO® Service, offers a proven approach to long-term continuous monitoring that enables diagnosis earlier in the clinical pathway to improve patient outcomes and reduce healthcare costs. For more information, please visit

Media Contact
Amanda Breeding
[email protected]

To view the original version on PR Newswire, visit:

SOURCE iRhythm Technologies, Inc.